Search | OpenScholar

Search results

1934 results found

Effect of SGLT2 inhibition on salt-induced hypertension in female Dahl SS rats

Publication: Journal Article

Kravtsova, O, V Levchenko, CA Klemens, T Rieg, R Liu, and A Staruschenko. 2023. “Effect of SGLT2 Inhibition on Salt-Induced Hypertension in Female Dahl SS Rats”. Scientific Reports.

Characterization of purinergic receptor expression in ARPKD cystic epithelia.

Publication: Journal Article

Palygin, O, DV Ilatovskaya, V Levchenko, CA Klemens, L Dissanayake, AM Williams, TS Pavlov, and A Staruschenko. 2018. “Characterization of Purinergic Receptor Expression in ARPKD Cystic Epithelia.”. Purinergic Signal.

Knockout of the Circadian Clock Protein PER1 (Period1) Exacerbates Hypertension and Increases Kidney Injury in Dahl Salt-Sensitive Rats.

Publication: Journal Article

Zietara, A, A Juffre, HM Costello, GR Crislip, LG Douma, V Levchenko, LV Dissanayake, et al. 2022. “Knockout of the Circadian Clock Protein PER1 (Period1) Exacerbates Hypertension and Increases Kidney Injury in Dahl Salt-Sensitive Rats.”. Hypertension.

Role of opioid signaling in kidney damage during the development of salt-induced hypertension

Publication: Journal Article

Golosova, D, O Palygin, R Bohovyk, CA Klemens, V Levchenko, E Isaeva, A El-Meanawy, and A Staruschenko. 2020. “Role of Opioid Signaling in Kidney Damage During the Development of Salt-Induced Hypertension”. Life Science Alliance.

Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.

Publication: Journal Article

Hauser, RA, AJ Espay, R Dhall, S Thakkar, L Cloud, L Zietlin, G Banisadr, S Fisher, and H Visser. 2024. “Safety and Efficacy of IPX203 in Parkinson’s Disease: The RISE-PD Open-Label Extension Study.”. Mov Disord. 2024 Feb;39(2):428-432. Doi: 10.1002/Mds.29685. Epub 2023 Dec 18. PMID: 38111267.

Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.

Publication: Journal Article

Hauser, RA, H Barkay, HH Fernandez, J Jimenez-Shahed, SA Factor, N Gross, L Marinelli, et al. 2024. “Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.”. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. Doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21.PMID: 38901008.

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Publication: Journal Article

Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-333.

Publication: Journal Article

Jenner, P, A Mori, SD Aradi, and RA Hauser. 2021. “Istradefylline - a First Generation Adenosine A2A antagonist for the Treatment of Parkinson’s Disease. Expert Rev Neurother 2021;21:317-333.”. Expert Rev Neurother.

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. doi: 10.1007/s40120-021-00256-1.

Publication: Journal Article

Hauser, RA, SH Mehta, D Kremens, D Chernick, and AE Formella. 2021. “Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. Doi: 10.1007/S40120-021-00256-1.”. Neurol Ther.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.

Publication: Journal Article

LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.